2197.HK

Biotechnology firm Clover Biopharmaceuticals Ltd. (2197.HK) said on Monday that it received an arbitration claim on June 6 seeking return of a $224 million prepayment from global vaccine alliance Gavi. Clover emphasized that based on the terms of the advance purchase agreement, the claim lacks merit.

The advance purchase agreement inked in 2021 stipulated that if Clover’s Covid vaccine should gained emergency use listing (EUL) approval from the World Health Organization (WHO), Gavi would procure 64 million doses from the company. The agreement also included an option for Gavi to purchase up to an additional 350 million doses.

However, delays in Clover’s vaccine development progress prompted the two parties to amend their agreement in September 2022. Despite that, delivery shortfalls persisted: as of 2025, Gavi reports having received just 12 million doses, a figure substantially below contracted volumes, driving its push for reimbursement of the prepayment.

Shares of Clover opened flat at HK$0.246 on Monday and were down slightly at the midday break. The stock is down around 60% from its 52-week high.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Noah does wealth management

Noah finds second life in overseas voyage

The wealth manager’s international businesses drove it back to revenue growth in the second quarter as challenges continued to linger at home Key Takeaways: Noah Holdings’ overseas revenue increased about…
Illustration of China solar industry

China moves to end solar bloodbath, as East Buy chases warehouse club crown

China is floating yet another plan to rescue its oversupplied solar sector, including a mass shuttering of excess capacity. Will the government-led effort work this time? And a former online educator says it wants to become the new online Sam's Club of China. Does East Buy have what it takes to succeed?